News in brief: Durable responses for brentuximab in CTCL; Blood 21 just a week away; Healthcare worker vaccination reduces COVID-19 transmission;

Durable responses for brentuximab in CTCL Final data from the phase 3 ALCANZA trial  have confirmed that treatment with brentuximab vedotin gives improved, durable responses and longer PFS compared to methotrexate or bexarotene in CD30+ CTCL. Brentuximab vedotin extended time to next treatment vs physician’s choice, suggesting that durable responses are clinically important. After a ...

Already a member?

Login to keep reading.

© 2021 the limbic